Blood cancers

Is a chemotherapy-free future now a possibility in relapsed, refractory CLL?

Sponsored by AbbVie Pty Ltd

At the Venclexta (venetoclax) in chronic lymphocytic leukaemia (CLL) meeting in Sydney last month, session chair Professor Stephen Mulligan, Director of Haematology at Laverty Pathology and Senior Staff Specialist Haematologist at Royal North Shore Hospital, Sydney set the bar high from the start. “It’s an exciting time for healthcare professionals who manage patients with CLL. ...

Already a member?

Login to keep reading.

© 2021 the limbic